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To characterize genetic variation of severe acute respi-
ratory syndrome–associated coronavirus (SARS-CoV)
transmitted in the Beijing area during the epidemic outbreak
of 2003, we sequenced 29 full-length S genes of SARS-CoV
from 20 hospitalized SARS patients on our unit, the Beijing
302 Hospital. Viral RNA templates for the S-gene amplifica-
tion were directly extracted from raw clinical samples,
including plasma, throat swab, sputum, and stool, during the
course of the epidemic in the Beijing area. We used a TA-
cloning assay with direct analysis of nested reverse tran-
scription–polymerase chain reaction products in sequence.
One hundred thirteen sequence variations with nine recur-
rent variant sites were identified in analyzed S-gene
sequences compared with the BJ01 strain of SARS-CoV.
Among them, eight variant sites were, we think, the first doc-
umented. Our findings demonstrate the coexistence of S-
gene sequences with and without substitutions (compared
to BJ01) in samples analyzed from some patients.
A
novel severe acute respiratory syndrome–associated
coronavirus (SARS-CoV) has been implicated as the
causative agent of a worldwide outbreak of SARS during
the first 6 months of 2003 (1–3). From March 4 to June 18,
Beijing had 2,521 cases and 192 deaths from SARS (4).
Because of the poor fidelity of RNA-dependent RNApoly-
merase, genetic variation typically forms a heterogeneous
virus pool in RNA virus populations, including coron-
aviruses such as mouse hepatitis virus (MHV) (5,6). This
feature makes viruses highly adaptable and contributes to
difficulties in preventing and controlling viral disease.
SARS-CoV, a single-stranded RNAvirus, has been report-
ed with relatively less variability in analyses of a limited
number of viral isolate collections (7–10). Furthermore, no
SARS-CoV quasispecies have been documented, as they
have been in many other RNA viruses, including hepatitis
C virus (HCV) (11), HIV (12), and MHV (6).
During the SARS outbreak in Beijing, 132 SARS
patients were hospitalized and treated on our unit at
Beijing Hospital, including the first cluster of case-patients
in the area (13). To characterize genetic variation among
SARS-CoV transmitted in the Beijing area, we sequenced
29 full-length S genes of SARS-CoV from 20 hospitalized
SARS patients, since S glycoprotein plays a key role in
virus-host interaction and is predicted to be the main target
of immune response (14). Samples that were analyzed rep-
resented the timespan of the epidemic. To exclude culture-
derived artifacts and estimate mutational heterogeneity,
viral RNA was directly extracted from raw clinical sam-
ples, and a TA-cloning assay was used with direct analysis
of reverse transcriptase–polymerase chain reaction (RT-
PCR) products. We compared these sequences with all pre-
viously documented S-gene sequences of SARS-CoV.
Materials and Methods
Patients and Samples
All patients in the study were hospitalized on our unit
with a confirmed diagnosis of SARS. Samples from
patients included plasma, throat swab, sputum, and stool;
these were stored at –70°C for extraction of viral RNA. A
total of 64 RNA samples from 28 SARS-CoV–positive
patients (detected by using BNI primers recommended by
the World Health Organization [15]) were initially used in
S-gene amplification, but only those that generated all six
overlapping fragments covering the full-length S-gene
sequence (see Nested RT-PCR below and Figure 1) were
included in the sequence analysis. As a result, 29 RNA
samples from 20 patients were included in the study
(Table 1). All patients had received ribavirin and steroid
combination therapy.
RNA Extraction
RNA extraction was performed in a biosafety level 3
(P3) laboratory. RNA was extracted directly from plasma
samples. Sputum samples were shaken for 30 min with an
equal volume of 1.0% acetylcysteine and 0.9% sodium
chloride, followed by isolating supernatant by centrifuging
(10,000 g x 3 min). Throat swab and stool samples were
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Headington, Oxford, United Kingdomsuspended with phosphate-buffered saline (PBS) contain-
ing 10 U/mL RNasin (Promega, Madison, WI) and shaken
for 10 min, followed by isolating supernatant by centrifug-
ing as mentioned above. RNA was extracted according to
the manufacturer’s instructions by using the QIAamp Viral
RNA Mini Kit (Qiagen, Hilden, Germany).
Nested RT-PCR
Screening RNA for SARS-CoV was based on the
method by Drosten et al. (1). For the S-gene amplification,
18 pairs of primers were designed by using MacVactor
computer software (Accelrys Inc, San Diego, CA) based
on the BJ01 strain of SARS-CoV (GenBank accession no.
AY278488) (16). Among them, six pairs (sense/antisense:
S1aF/S1aB, S2aF/S2aB, S3aF/S3aB, S4aF/S4aB,
S5aF/S5aB, S6aF/S6aB) were used as outer primers, six
pairs (sense/antisense: S1bF/S1bB, S2bF/S2bB,
S3bF/S3bB, S4bF/S4bB, S5bF/S5bB, S6bF/S6bB) were
used as inner primers, and six pairs (sense/antisense:
S1cF/S1cB, S2cF/S2cB, S3cF/S3cB, S4cF/S4cB,
S5cF/S5cB, S6cF/S6cB) were designed for direct RT-PCR
product sequencing. The sequences covering the full-
length S gene were amplified separately as six overlapping
fragments (F1b, F2b, F3b, F4b, F5b, and F6b) (Figure 1).
The one-step RT-PCR Kit (Qiagen) was used for reverse
transcription and the first round of PCR amplification with
outer primers. Thermal cycling consisted of 50°C for 30
min; 95°C for 15 min; 10 cycles of 95°C for 30 s, 57.5°C
for 30 s (decreasing by 1.5°C every other cycle), 72°C for
1 min; 40 cycles of 95°C for 30 s, 54°C for 30 s, 72°C for
1 min. Afterwards, 2 µL of the product was used as a tem-
plate for the second round of PCR amplification in 100-µL
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Figure. 1. Diagram showing amplification of six overlapping frag-
ments covering full-length spike gene sequence of severe acute
respiratory syndrome–associated coronavirus by nested reverse
transcriptase–polymerase chain reaction.
Table 1. Clinical backgrounds of patients and sample collection 
Patient no.  Age (y)  Sex
a  Onset date  Hospitalized date  Specimen no.
b  Sampling date 
1  53  M  2/28  3/05  SW6  3/06 
2  32  M  3/08  3/08  SW17  3/09 
3  32  F  3/20  4/04  PL1  4/07 
4  20  M  3/21  4/06  PL10  4/07 
          PL17  4/22 
          SP4  5/03 
5  33  M  3/28  4/04  PL9  4/07 
          SP1  5/03 
6  59  M  3/30  4/06  PL5  4/07 
          SP9  5/12 
7  52  M  3/30  4/04  PL7  4/07 
8  59  M  3/30  4/06  PL8  4/07 
9  19  F  4/01  4/12  PL15  4/22 
          SP32  4/26 
10  73  M  4/02  4/03  PL6  4/07 
          SP62  4/18 
          SW73  4/21 
11  45  F  4/04  4/04  SP67  4/18 
12  26  M  4/08  4/18  SW76  4/21 
13  31  M  4/08  4/14  ST123  4/26 
14  32  M  4/09  4/18  PL57  4/21 
          SW77  4/22 
15  39  M  4/10  4/10  SP61  4/18 
16  31  F  4/10  4/12  PL59  4/30 
17  46  F  4/20  4/21  SP28  4/26 
18  48  M  4/20  4/22  SP43  4/24 
19  38  M  4/22  4/26  SP13  5/03 
          ST158  4/30 
20  27  M  5/10  5/11  SP8  5/12 
aM, male; F, female. 
bFirst two letters indicate source of sample: SW, throat swab; PL, plasma; SP, sputum; ST, stool. volume with inner primers with Taq DNA polymerase
(MBI Fermentas, Hanover, MD). Thermal cycling consist-
ed of 30 cycles of 95°C for 25 s, 54°C for 25 s, 72°C for
50 s. In some cases, superScript III RNase Reverse
Transcriptase (Invitrogen, Carlsbad, CA) was used for
reverse transcription, according to the manufacturer’s
instructions. The next two rounds of PCR amplification
were performed by using Platinum Pfx DNA Polymerase
with a higher fidelity (Invitrogen). The reaction condition
was set as above, with a twofold elongation at 68°C
instead of 72°C. All reactions were carefully carried out to
avoid contamination. 
TA-Cloning
RT-PCR products were purified by QIAquick PCR
Purification Kit (Qiagen) or QIAquick Gel Extraction Kit
(Qiagen), with a final volume of 30 µL of elution. The lig-
ation and transformation were performed according to the
manufacturer’s instructions by using pGEM-T Vector
System II (Promega). Transformants were selected in LB-
agar plate containing 100 µg of ampicillin, 100 µg of 5-
bromo-4-chloro-3-indolyl  β-L-fucopyranoside (X-gal),
and 200 µg of isopropylthiogalactoside. Escherichia coli
from white clones was added to 5 mL of LB culture for
overnight growing at 37°C with vigorous shaking. Plasmid
was purified by QIAprep Spin Miniprep Kit (Qiagen). The
recombinant plasmids for sampling sequence analysis
were screened by electrophoresis in 1% agarose containing
0.5 µg/mL of ethidium bromide. 
Sequencing and DNA Analysis
For each S-gene fragment, four to six clones were
screened. To verify variations, 5–50 additional clones gen-
erated from independently prepared, RNA-derived RT-
PCR products were sequenced in two to four independent
experiments. The cloned plasmids were prepared from dif-
ferent RT-PCR products and were directly sequenced for
confirmation. DNA sequences were obtained with the use
of an automated ABI 377 sequencer (Applied Biosystems
Inc., Foster City, CA). For cloned plasmids, SP6 and T7
primers were used for two-directional sequencing reac-
tions. For PCR products, specific primers (sense:
S1cF–S6cF; antisense: S1cB–S6cB) were used for two-
directional sequencing reactions. Analysis and comparison
of nucleotide and amino acid sequences were carried out
with the DNASTAR computer software (DNASTAR Inc.,
Madison, WI). The S gene sequence of BJ01 strain was
taken as the reference for variation analysis. 
Results
With the designed six pairs of primers, all six overlap-
ping S-gene fragments were amplified by nested RT-PCR
from 29 RNA samples. However, most RNA samples ini-
tially included in the study, though positive for SARS-CoV
with BNI primers, failed to simultaneously generate all six
overlapping S-gene fragments and were excluded from
further sequence analysis. Disintegration of the virus and
low viral load in the raw samples likely accounted for
these failures.
One hundred and thirteen sequence variations distrib-
uted in nine variant sites were identified in analyzed
sequences that were compared to the reference BJ01 strain
of SARS-CoV. BJ01 is an isolate from a tissue-culture
propagated sample (16) and is used as reference strain in
other studies (9,10). With the exception of one site (posi-
tion 21702), other variant sites have not, to our knowledge,
been documented in humans. Seven of nine variant sites
were nonsynonymous. Figure 2 shows the identified vari-
ant sites compared to the reference sequence.
Discussion
We identified novel variant sites and the coexistence of
sequences with and without S-gene substitutions in SARS-
CoV. Theoretically, a replicating RNA virus expresses a
range of genetic and phenotypic variants and has the
potential to generate novel virions, which may be selected
in response to environmental pressures. RNA viruses gen-
erally tolerate high levels of mutagenesis because of their
limited genetic complexity (17). Mutations have the poten-
tial to be pathogenic (e.g., giving the virus immunity to
neutralizing antibodies, cytotoxic Tcells, or antiviral drugs
[18–20]). The dynamics of error copying and sequence
decomposition are time-dependent. In HIV infection, for
example, one adaptive substitution in the env gene
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Figure 2. Variants identified from 29 full-length S genes of severe
acute respiratory syndrome–associated coronavirus from 20
SARS patients in comparison with BJ01 strain (GenBank acces-
sion no. AY278488). The nucleotide positions are numbered
according to the sequence of BJ01 strain. Numbers start from the
beginning of the genome, but the amino acid numbers start from
the S protein. The filled arrows represent nonsynonymous muta-
tions, and the hollow arrows represent synonymous ones. The
occurrence indicates the frequency of the variant nucleotide at the
given site of the identified 29 entire S genes.occurred every 3.3 months or 25 viral generations, averag-
ing across patients (21). 
In our study, a higher variation frequency in the S gene
was identified for SARS-CoV compared to previous
reports (7–10). This difference may be due to a broader
sample collection covering a longer timespan of infection.
In addition, since virus isolates were not passaged in cul-
ture, the whole mutant repertoire is more likely to be
detected, since no reverse mutation occurs in cell culture.
Our observation most likely reflected the real situation in
vivo. Variations were unlikely to result from Taq poly-
merase errors, since we repeated the experiments for all
variations from preparing independent RNA and RT-PCR
products and used Platinum Pfx DNA polymerase, which
has a high fidelity, to confirm the results in some cases. We
could not exclude the possibility that some variations were
from defective genomes. However, the fact that the varia-
tions remained detectable in the sequences from two or
three specimens of the same patient, obtained at different
times, suggested that these variations might be active and
extensible in vivo. 
Sequences with and without substitutions (compared to
BJ01) were simultaneously detected in the sequences from
seven samples, which suggests the existence of SARS-
CoV quasispecies. Furthermore, S-gene sequences from
different samples collected at different times from the
same patient showed similar, but not exactly identical,
variation profiles in four participants (patients 4, 5, 6, and
19 in Table 1); this implies that a dynamic mutational
process may exist in vivo. Table 2 summarizes the varia-
tions occurring in 29 analyzed S-gene sequences from 20
individual SARS patients.
One nonsynonymous change observed at position
A1023G is within the heptad repeat (HR) domains, which
is thought to be important for virus entry, and previous
study on MHV showed that it would have some effect on
virus infection (22). At this stage, we cannot rule out the
possibility that this change affects the biological outcome
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Table 2. Variation in S-gene sequences from 20 individual SARS patients
a,b 
21494  21702  21858  22908  23198  24018  24247  24469  24540 
Pt. no.  Samp. no.  C→T  A→G  A→T  A→G  T→C  A→T  T→C  A→G  A→G 
1  SW6  –  –  –  –  –  –  –  –  – 
2  SW17  9/2
c  +  –  –  –  –  +  –  – 
3  PL1  8/39  8/43  48/2  +  +  +  +  +  + 
4    PL10  14/7  +  –  +  +  2/8  +  +  + 
  PL17  +  +  –  –  –  +  +  +  + 
  SP4  –  +  –  +  –  +  +  +  + 
5  PL9  +  +  –  +  +  +  +  +  + 
  SP1  –  +  –  +  +  –  +  +  + 
6  PL5  –  +  –  +  +  8/4  +  +  + 
  SP9  –  +  –  +  +  +  +  +  + 
7  PL7  –  +  –  +  +  4/6  +  +  + 
8  PL8  7/28  +  33/2  +  +  +  +  +  + 
9  SP15  –  +  –  –  –  –  –  –  – 
  SP32  –  +  –  –  –  –  –  –  – 
10  SP6  –  –  –  –  –  –  –  –  – 
  SP62  –  –  –  –  –  –  –  –  – 
  SW73  –  –  –  –  –  –  –  –  – 
11  SP67  –  +  –  –  –  –  –  –  – 
12  SW76  –  +  –  –  –  –  –  –  – 
13  ST123  –  +  –  –  –  –  –  –  – 
14  PL57  –  +  –  –  +  +  +  +  + 
  SW77  –  +  –  –  +  +  +  +  + 
15  SP61  –  +  –  –  –  –  –  –  – 
16  PL59  –  –  –  –  –  –  –  –  – 
17  SP28  –  +  –  –  –  –  –  –  – 
18  SP43  –  +  –  –  –  –  –  –  – 
19  ST158  –  +  –  +  +  +  +  +  + 
  SP13  19/4  14/10  10/13  +  +  +  6/16  +  14/8 
20  SP8  –  +  –  –  –  –  –  –  – 
aThe results were determined by analysis of cloned sequences; + represents that nucleotide substitution at the variant site is detected and – represents that the nucleotide 
at the site is identical to the one of BJ01 reference sequence in all analyzed sequences.   
bSARS, severe acute respiratory syndrome; SW, throat swab; PL, plasma; SP, sputum; ST, stool. 
cThe numbers represent the ratio of reference to variant nucleotide detected at the site from the analyzed cloned sequences. of the virus, but further experiments need to be addressed
in the near future. 
We observed the coexistence of the S-gene sequences
with and without substitutions and time-dependent varia-
tion profile in some patients. These observations suggest
the possible existence of SARS-CoV quasispecies in an
acute infection. In this study, however, the limitation of
clinical sample collection and difficulty in directly ampli-
fying full-length S gene from raw clinical samples restrict-
ed further extensive study for dynamic mutant
distributions of the virus. In addition, the sequencing clone
number was conditioned by the scale of the project, and
this may have led to some minor variant sequences escap-
ing analysis. Another factor possibly affecting the stability
of the viral genome is the administration of the antiviral
drug ribavirin. That ribavirin enhances mutagensis of RNA
viruses has been addressed (23). Therefore, the artificial
effect of ribavirin on the SARS-CoV mutant spectrum
remains to be clarified. 
The genetic variation of SARS-CoV remains limited in
relation to many other RNA viruses such as HIV-1, HCV,
and MHV. The probable reason is that SARS-CoV only
causes an acute, self-limited infection, which may prevent
persistent long-term mutant development in vivo as occurs
in chronic RNAviral infections. Notably, some modules in
the S protein remain conserved, e.g., the fusion-important
HR domains. Although some variations may predict
changes of protein functional features, no obvious correla-
tion exists between mutation and clinical disease manifes-
tation from the limited data reported here. Instead, the
variation profile was closely correlated with epidemiogra-
phy; e.g., patients 3–8 were infected in one hospital. 
In conclusion, we report here some new variant sites in
the S gene of SARS coronavirus and possible existence of
SARS-CoV quasispecies in some patients, though in limit-
ed numbers. This knowledge furthers our understanding of
this emerging virus.
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